Management of Intractable Headache in Elevated Intracranial Pressure

Understanding the Headache Phenotype

68% of patients with elevated ICP from idiopathic intracranial hypertension have a migrainous headache phenotype superimposed on their pressure-related headache, which explains why simply lowering ICP often fails to resolve headache symptoms 2, 1

The American College of Neurology recommends starting topiramate at 25 mg with weekly escalation to 50 mg twice daily, as it provides carbonic anhydrase inhibition to lower ICP, weight loss promotion, and migraine prophylaxis 2, 1, 3
Counsel patients about side effects of topiramate including depression, cognitive slowing, reduced contraceptive efficacy, and teratogenic risks, and consider alternative contraception methods for women of childbearing age 3, 2

Consider candesartan for patients with migrainous features, as it avoids weight gain and depressive side effects, and is particularly important since weight gain worsens IIH and depression is a frequent comorbidity 3, 2, 1
Venlafaxine is weight-neutral and addresses comorbid depression, making it a suitable alternative for patients who cannot tolerate topiramate 3, 2, 1

CSF diversion is generally NOT recommended for headache management alone, as 68% of patients continue having headaches at 6 months post-procedure and 79% have persistent headaches at 2 years 3, 4, 2, 1
Neurovascular stenting is not currently a treatment for headache in IIH, due to lack of randomized trials, selection bias, small sample sizes, and insufficient long-term follow-up 3, 4, 1

Implement comprehensive lifestyle modifications, including limiting caffeine intake, ensuring regular meals and adequate hydration, establishing an exercise program and sleep hygiene protocols, and considering behavioral interventions such as cognitive-behavioral therapy, mindfulness, and yoga 1
Weight loss remains foundational to treatment and should be emphasized throughout management, as it addresses a root cause of IIH 2, 1

Elevate head of bed to 30 degrees with head midline to improve jugular venous outflow, ensuring patient is not hypovolemic first, as recommended by the American Heart Association 6
Provide adequate analgesia and sedation with propofol, etomidate, or midazolam for sedation and morphine or alfentanil for analgesia, to minimize pain-induced ICP elevations 6

Failing to recognize the migrainous component and treating only the elevated ICP, which can lead to inadequate treatment and poor patient outcomes 1
Using weight-promoting medications that worsen underlying IIH, such as beta-blockers, tricyclic antidepressants, sodium valproate, pizotifen, and flunarizine 1
Not starting preventative medications early enough, given their 3-4 month onset, which can delay effective treatment and worsen patient outcomes 1
Relying on CSF diversion for headache control without addressing migraine features, which can lead to inadequate treatment and poor patient outcomes 1
Allowing medication overuse headache to develop through inadequate acute medication limits, which can worsen patient outcomes and reduce treatment effectiveness 2, 1